#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Acute myeloid leukaemia Neoplasm malignant Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Ovarian cancer Colorectal cancer Hepatocellular carcinoma Dermatitis atopic Dementia Alzheimer's type Asthma Breast cancer metastatic Type 2 diabetes mellitus Non-small cell lung cancer metastatic More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Acute on chronic liver failure Cytokine release syndrome Neurodegenerative disorder Congenital hypotransferrinaemia Gaucher's disease type I Angiosarcoma metastatic Sickle cell disease Congenital absence of bile ducts Cardiomyopathy Chronic myeloid leukaemia Giant cell tumour of tendon sheath Dermatitis Renal cell carcinoma Ependymoma Von Hippel-Lindau disease More trials…

    Learn about Rare Diseases

    Glycogen storage disease type V – Life with Disease Rosai-Dorfman syndrome – Treatment Paraneoplastic neurological syndrome – Diagnostics Hypereosinophilic syndrome Rosai-Dorfman syndrome – Trials in Disease Chondrosarcoma metastatic Von Willebrand’s disease – Life with Disease MELAS syndrome – Life with Disease Rosai-Dorfman syndrome Mast cell activation syndrome – Diagnostics More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    LUXDEGALUTAMIDE Cenerimod Ofloxacin Hydrochloride L-Histidine Hydrochloride NALMEFENE HYDROCHLORIDE Propylene Glycol Delafloxacin Clemastine Fumarate Mecillinam Bi 1015550 Donidalorsen Imidapril Hydrochloride Ep0031 Melphalan Flufenamide (-)-PHENSERINE TARTRATE Vosilasarm Pantothenate Sodium FOSMANOGEPIX AGALSIDASE BETA RIMIDUCID More therapies…

    Learn about Your Condition

    Alveolar bone defect Colon cancer stage II Colitis Vaginal haemorrhage Endometriosis Head injury Staphylococcal bacteraemia Pathogen resistance Vulvovaginal pain Infertility female B-cell lymphoma recurrent Postprandial hypoglycaemia Thyroid disorder Essential thrombocythaemia Non-obstructive cardiomyopathy More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden
  1. Clinicaltrials.eu/
  2. Krankenhaus Nordwest GmbH

Krankenhaus Nordwest GmbH

Steinbacher Hohl 2-26, Praunheim, Frankfurt, 60488, Germany

Want to learn more about this study or check if you can participate? Contact us.

  • Randomized Study of INCB161734 Plus Standard Chemotherapy Drug Combination in Untreated KRAS G12D Metastatic Pancreatic Ductal Adenocarcinoma Patients

    Recruiting

    3 1 1
    Investigated Drugs:
    • Calcium Folinate
    • Fluorouracil
    • Gemcitabine
    Austria Belgium Denmark Finland France Germany +6

  • Durvalumab plus drug combination as total neoadjuvant therapy for patients with resectable gastroesophageal adenocarcinoma

    Recruiting

    2 1 1 1
    Investigated Diseases:
    • Oesophageal adenocarcinoma
    Investigated Drugs:
    • Calcium Folinate
    • Docetaxel
    • Durvalumab
    Germany Spain

  • Study of precemtabart tocentecan alone or in drug combination versus standard therapy in previously treated metastatic colorectal cancer patients

    Recruiting

    3 1 1 1
    Investigated Diseases:
    • Colorectal cancer metastatic
    Investigated Drugs:
    • Bevacizumab
    • Tipiracil Hydrochloride
    • Trifluridine
    Austria Belgium Denmark France Germany Italy +3

  • Comparing Daraxonrasib Alone or Combined with Gemcitabine and Paclitaxel Albumin‑Bound vs Standard Chemotherapy in Patients with Metastatic Pancreatic Adenocarcinoma

    Recruiting

    3 1 1 1
    Investigated Drugs:
    • (12M)-(1S,2S)-N-((63S,4S,Z)-11-ETHYL-12-(2-((S)-1-METHOXYETHYL)-5-(4-METHYLPIPERAZIN-1-YL)PYRIDIN-3-YL)-10,10-DIMETHYL-5,7-DIOXO-61,62,63,64,65,66-HEXAHYDRO-11H-8-OXA-2(4,2)-THIAZOLA-1(5,3)-INDOLA-6(1,3)-PYRIDAZINACYCLOUNDECAPHANE-4-YL)-2-METHYLCYCLOPROPANE-1-CARBOXAMIDE
    • Gemcitabine
    • Paclitaxel Albumin-Bound
    Austria Belgium Denmark France Germany Italy +5

  • Study of AZD0901 (sonesitatug vedotin) with capecitabine ± rilvegostomig in adults with advanced stomach or esophageal cancer (Claudin‑18.2‑positive, HER2‑negative)

    Recruiting

    3 1 1 1
    Investigated Diseases:
    • Oesophageal adenocarcinoma
    • Gastric cancer
    Investigated Drugs:
    • Azd0901
    • Capecitabine
    • Fluorouracil
    Belgium France Germany Hungary Italy The Netherlands +2

  • INCA33890 With Standard Chemotherapy and Bevacizumab in First-Line Treatment of Metastatic Microsatellite Stable Colorectal Cancer

    Recruiting

    3 1 1
    Investigated Diseases:
    • Colorectal cancer metastatic
    Investigated Drugs:
    • Bevacizumab
    • Calcium Folinate
    • Fluorouracil
    Austria Belgium Denmark France Germany Italy +4

  • Volrustomig in Patients with Unresectable Pleural Mesothelioma and Esophageal Squamous Cell Carcinoma

    Recruiting

    2 1 1 1
    Investigated Diseases:
    • Neoplasm
    Investigated Drugs:
    • Volrustomig
    • Cisplatin
    • Fluorouracil
    Germany Italy

  • A study of loxo-435, enfortumab vedotin, and pembrolizumab in adults with advanced or metastatic bladder cancer

    Recruiting

    3 1 1
    Investigated Diseases:
    • Bladder cancer
    • Bladder transitional cell carcinoma
    Investigated Drugs:
    • (S)-4-(4-(3-CHLORO-4-(1-(5-FLUOROPYRIDIN-2-YL)-2-HYDROXYETHOXY)PYRAZOLO[1,5-A]PYRIDIN-6-YL)-5-METHYL-1H-1,2,3-TRIAZOL-1-YL)PIPERIDINE-1-CARBONITRILE
    • Enfortumab Vedotin
    • Pembrolizumab
    Czechia Denmark France Germany Hungary Italy +3

  • A study of PF-08634404 and sigvotatug vedotin in patients with advanced solid tumors

    Recruiting

    1 1 1
    Investigated Diseases:
    • Non-small cell lung cancer stage IIIB
    • Squamous cell carcinoma of lung
    • Non-small cell lung cancer
    Investigated Drugs:
    • SIGVOTATUG VEDOTIN
    • HUMANISED IGG1 MONOCLONAL ANTIBODY AGAINST PD-L1 CONJUGATED TO MONOMETHYL AURISTATIN E VIA A VALINE-CITRULLINE LINKER
    France Germany Italy Spain

  • A study of PF-08634404 and a drug combination for adult patients with extensive-stage small cell lung cancer

    Recruiting

    4 1 1 1
    Investigated Diseases:
    • Small cell lung cancer extensive stage
    Investigated Drugs:
    • Atezolizumab
    • Carboplatin
    • Etoposide
    France Germany Italy Spain
1 2 3 … 14
Next Page

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!